Prophylaxis of atopic and allergic manifestations and activation or modulation of the immune system by Pro-Symbioflor® treatment in newborns / small children from atopically pre-disposed parents.

ISRCTN ISRCTN60475069
DOI https://doi.org/10.1186/ISRCTN60475069
Secondary identifying numbers N/A
Submission date
21/07/2010
Registration date
15/09/2010
Last edited
13/11/2013
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Skin and Connective Tissue Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Study website

Contact information

Prof Ulrich Wahn
Scientific

Department of Pediatric Pneumology and Immunology
(Klinik für Pädiatrie mit Schwerpunkt Pneumologie und Immunologie)
Charité
Augustenburger Platz 1
Berlin
13353
Germany

Email marina.birr@charite.de

Study information

Study designProspective randomised placebo controlled double blind parallel group trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typePrevention
Participant information sheet Not available in web format, please use contact details below to request a patient information sheet
Scientific titleProphylaxis by Pro-Symbioflor® of atopic and allergic manifestations and activation or modulation of the immune system in newborns / small children from atopically pre-disposed parents. Prospective, randomized, placebo-controlled, double-blind parallel group trial in 632 healthy newborns aged 4 weeks with increased risk for atopic dermatitis with repeated application of Pro-Symbioflor® t.i.d or placebo between 2 and 7 months of age and an observation period until the age of 3 years.
Study acronymPAPS
Study objectivesPro-Symbioflor® is an immunologically active product containing components of a mixture of Escherichia coli (gram negative) and Enterococcus faecalis (gram positive).
Pro-Symbioflor® is claimed to be effective as an immunomodulatory acting drug in the primary prevention of atopic dermatitis and other allergic diseases. To prove this, a trial was designed to test for the Verum - Placebo superiority in the preventive efficacy lowering the risk to develop an atopic disease under a 6 months lasting prophylactic treatment with Pro-Symbioflor® in newborns/ small children aged between 4 weeks and 3 years. In addition its immunomodulatory effects were to be studied.
Null hypothesis H0: The risk of a manifestation of atopic dermatitis (AD) under treatment verum or placebo is not different. Alternative hypothesis H1: The risk of a manifestation of AD under treatment with verum is twice as low as under placebo.
Ethics approval(s)1. The independent ethics committee (IEC) at Charité approved on the 2nd of March 2002 (ref: 19/2002)
2. Intermediate evaluation of the study (half of cases completed) was carried out and approval to continue granted on the 21st of October 2005
3. Amendment to the protocol approved on the 7th of March 2007
Health condition(s) or problem(s) studiedAtopic dermatitis
Intervention1. Intervention group:
Pro-Symbioflor® (verum): Bacterial lysate manufactured from 1,5 – 4,5 x 10E+07 Enterococcus faecalis (DSM 16440) and 1,5 – 4,5 x 10E+07 Escherichia coli (DSM 17252). 3x5 drops per day for 2 weeks then increased to 3x10 drops per day between 2 and 7 months of age.
2. Control group:
Pro-Symbioflor® (placebo): Culture medium without bacteria. 3x5 drops daily, for 2 weeks increased to 3x10 drops daily between 2 and 7 months of age.

The total duration of follow up will be 3 years.
Intervention typeOther
Primary outcome measureIncidence of atopic dermatitis during the treatment phase between the 4th and 31st life week under the prophylaxis with verum or placebo.
Secondary outcome measures1. Incidence of atopic dermatitis after treatment and until end of 3 years
2. Time until the first manifestation of an AD
3. Severity of AD at manifestation of an eczema: SCORing Atopic Dermatitis (SCORAD) Score
4. Frequency and time until the appearance as well as severity of allergic/atopic manifestations in the gastrointestinal tract
5. Frequency and until the appearance as well as severity of an allergic/atopic manifestation in the airways
6. Frequency of a sensitization against food allergens
7. Induction / enhancement of a Th1-immune response
8. Toll-like-receptors
9. Safety pharmacological Investigations before and at the end of the treatment as well as the observation period
10. Adverse events
Overall study start date28/05/2002
Completion date19/09/2010

Eligibility

Participant type(s)Patient
Age groupNeonate
SexBoth
Target number of participants632
Key inclusion criteria1. Healthy male and female newborns aged 4 weeks
2. Regularly developed newborns - body weight: ≥ 2500 g; gestational age > 37+0 weeks
3. No relevant illnesses since the birth (except transient Hyperbilirubinemia)
4. Positive atopic anamnesis with at least one parent (atopic dermatitis, bronchial asthma, allergic rhino-conjunctivitis)
5. Written informed consent by the parents as the legal representatives
Key exclusion criteria1. Diseases that require immunosuppressive therapy (systemic administration of steroids or cyclosporine A)
2. Transfer to an intensive care unit after birth
3. Known immune disturbances or defects (Lymphopenia, Thrombopenia)
4. Concomitant medication or treatment (except for prophylaxis)
5. Inadequate ability or willingness of the parents to communicate or to cooperate
6. Family anamnesis of a congenital deficiency in immune defence
Date of first enrolment28/05/2002
Date of final enrolment19/09/2010

Locations

Countries of recruitment

  • Germany

Study participating centre

Department of Pediatric Pneumology and Immunology
Berlin
13353
Germany

Sponsor information

SymbioPharm GmbH (Germany)
Industry

Auf den Lüppen 8
Herborn
35745
Germany

Email kurt.zimmermann@symbio.de
Website http://www.symbiopharm.de
ROR logo "ROR" https://ror.org/03d8m2k26

Funders

Funder type

Industry

Symbiopharm GmbH (Germany)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/09/2013 Yes No